ID   VKOR1_HUMAN             Reviewed;         163 AA.
AC   Q9BQB6; A6NIQ6; B2R4Z6; Q6UX90; Q7Z2R4;
DT   12-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   15-MAR-2017, entry version 134.
DE   RecName: Full=Vitamin K epoxide reductase complex subunit 1;
DE            EC=1.17.4.4 {ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610};
DE   AltName: Full=Vitamin K1 2,3-epoxide reductase subunit 1;
GN   Name=VKORC1; Synonyms=VKOR; ORFNames=MSTP134, MSTP576, UNQ308/PRO351;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, VARIANTS CMRES LEU-29; ALA-45; GLY-58
RP   AND ARG-128, AND VARIANT VKCFD2 TRP-98.
RC   TISSUE=Kidney;
RX   PubMed=14765194; DOI=10.1038/nature02214;
RA   Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hoertnagel K.,
RA   Pelz H.-J., Lappegard K., Seifried E., Scharrer I., Tuddenham E.G.D.,
RA   Mueller C.R., Strom T.M., Oldenburg J.;
RT   "Mutations in VKORC1 cause warfarin resistance and multiple
RT   coagulation factor deficiency type 2.";
RL   Nature 427:537-541(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=14765195; DOI=10.1038/nature02254;
RA   Li T., Chang C.-Y., Jin D.-Y., Lin P.-J., Khvorova A., Stafford D.W.;
RT   "Identification of the gene for vitamin K epoxide reductase.";
RL   Nature 427:541-544(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Aorta;
RA   Liu B., Qin B.M., Sheng H., Zhao B., Liu Y.Q., Wang X.Y., Zhang Q.,
RA   Song L., Lu H., Xu H.S., Zheng W.Y., Gong J., Wang Y.B., Liu Y.Q.,
RA   Zhang C.N., Shi Y., Wang W., Zhang Z., Yang X., Han Y., Chen J.Z.,
RA   Liu B.H., Hui R.T.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 44-163 (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [10]
RP   POTENTIAL REDOX-ACTIVE SITE.
RX   PubMed=15276181; DOI=10.1016/j.tibs.2004.04.004;
RA   Goodstadt L., Ponting C.P.;
RT   "Vitamin K epoxide reductase: homology, active site and catalytic
RT   mechanism.";
RL   Trends Biochem. Sci. 29:289-292(2004).
RN   [11]
RP   MUTAGENESIS OF ARG-35; SER-56; LEU-120; LEU-128 AND TYR-139, CATALYTIC
RP   ACTIVITY, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=15879509; DOI=10.1534/genetics.104.040360;
RA   Pelz H.J., Rost S., Hunerberg M., Fregin A., Heiberg A.C., Baert K.,
RA   MacNicoll A.D., Prescott C.V., Walker A.S., Oldenburg J., Muller C.R.;
RT   "The genetic basis of resistance to anticoagulants in rodents.";
RL   Genetics 170:1839-1847(2005).
RN   [12]
RP   TOPOLOGY, AND SUBCELLULAR LOCATION.
RX   PubMed=15716279; DOI=10.1074/jbc.M500765200;
RA   Tie J.-K., Nicchitta C., von Heijne G., Stafford D.W.;
RT   "Membrane topology mapping of vitamin K epoxide reductase by in vitro
RT   translation/cotranslocation.";
RL   J. Biol. Chem. 280:16410-16416(2005).
RN   [13]
RP   FUNCTION, POTENTIAL REDOX-ACTIVE SITE, CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, SUBCELLULAR LOCATION, MUTAGENESIS OF CYS-16; CYS-43;
RP   CYS-51; SER-57; CYS-85; CYS-96; ARG-98; CYS-132; CYS-135 AND TYR-139,
RP   AND CHARACTERIZATION OF VARIANT VKCFD2 TRP-98.
RX   PubMed=16270630; DOI=10.1160/TH05-02-0082;
RA   Rost S., Fregin A., Hunerberg M., Bevans C.G., Muller C.R.,
RA   Oldenburg J.;
RT   "Site-directed mutagenesis of coumarin-type anticoagulant-sensitive
RT   VKORC1: evidence that highly conserved amino acids define structural
RT   requirements for enzymatic activity and inhibition by warfarin.";
RL   Thromb. Haemost. 94:780-786(2005).
RN   [14]
RP   TOPOLOGY.
RX   PubMed=20696932; DOI=10.1073/pnas.1009972107;
RA   Schulman S., Wang B., Li W., Rapoport T.A.;
RT   "Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-
RT   like redox partners.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15027-15032(2010).
RN   [15]
RP   CATALYTIC ACTIVITY, FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, AND
RP   MUTAGENESIS OF CYS-43 AND CYS-51.
RX   PubMed=20978134; DOI=10.1074/jbc.M110.172213;
RA   Rishavy M.A., Usubalieva A., Hallgren K.W., Berkner K.L.;
RT   "Novel insight into the mechanism of the vitamin K oxidoreductase
RT   (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow
RT   vitamin K reduction and facilitation of vitamin K-dependent protein
RT   carboxylation.";
RL   J. Biol. Chem. 286:7267-7278(2011).
RN   [16]
RP   SUBCELLULAR LOCATION, TOPOLOGY, CATALYTIC ACTIVITY, ENZYME REGULATION,
RP   AND FUNCTION.
RX   PubMed=22923610; DOI=10.1074/jbc.M112.402941;
RA   Tie J.K., Jin D.Y., Stafford D.W.;
RT   "Human vitamin K epoxide reductase and its bacterial homologue have
RT   different membrane topologies and reaction mechanisms.";
RL   J. Biol. Chem. 287:33945-33955(2012).
RN   [17]
RP   3D-STRUCTURE MODELING.
RX   PubMed=24406068; DOI=10.1111/jth.12450;
RA   Wu S., Tie J.K., Stafford D.W., Pedersen L.G.;
RT   "Membrane topology for human vitamin K epoxide reductase.";
RL   J. Thromb. Haemost. 12:112-114(2014).
RN   [18]
RP   VARIANTS CMRES THR-26; LEU-29; GLY-36; TYR-36; TRP-52; PHE-56; LEU-59;
RP   CYS-59; GLY-66; MET-66; ALA-71; SER-77; TYR-77; ASN-123 AND HIS-139.
RX   PubMed=20946155; DOI=10.1111/j.1538-7836.2010.04095.x;
RA   Watzka M., Geisen C., Bevans C.G., Sittinger K., Spohn G., Rost S.,
RA   Seifried E., Muller C.R., Oldenburg J.;
RT   "Thirteen novel VKORC1 mutations associated with oral anticoagulant
RT   resistance: insights into improved patient diagnosis and treatment.";
RL   J. Thromb. Haemost. 9:109-118(2011).
CC   -!- FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of
CC       the vitamin K epoxide reductase (VKOR) complex which reduces
CC       inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is
CC       required for the gamma-carboxylation of various proteins,
CC       including clotting factors, and is required for normal blood
CC       coagulation, but also for normal bone development.
CC       {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:14765195,
CC       ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630,
CC       ECO:0000269|PubMed:20978134, ECO:0000269|PubMed:22923610}.
CC   -!- CATALYTIC ACTIVITY: Phylloquinone + oxidized dithiothreitol +
CC       H(2)O = 2,3-epoxy-2-methyl-3-phytyl-2,3-dihydro-1,4-naphthoquinone
CC       + 1,4-dithiothreitol. {ECO:0000269|PubMed:15879509,
CC       ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134,
CC       ECO:0000269|PubMed:22923610}.
CC   -!- ENZYME REGULATION: Inhibited by warfarin (coumadin).
CC       {ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:16270630,
CC       ECO:0000269|PubMed:22923610}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:15716279,
CC       ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134,
CC       ECO:0000269|PubMed:22923610}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:14765194, ECO:0000269|PubMed:15716279,
CC       ECO:0000269|PubMed:16270630, ECO:0000269|PubMed:20978134,
CC       ECO:0000269|PubMed:22923610}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=MST576;
CC         IsoId=Q9BQB6-1; Sequence=Displayed;
CC       Name=2; Synonyms=MST134;
CC         IsoId=Q9BQB6-2; Sequence=VSP_013363;
CC       Name=3;
CC         IsoId=Q9BQB6-3; Sequence=VSP_043407;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed at highest levels in fetal and adult
CC       liver, followed by fetal heart, kidney, and lung, adult heart, and
CC       pancreas. {ECO:0000269|PubMed:14765194}.
CC   -!- DOMAIN: The number of transmembrane domains and the membrane
CC       topology are controversial; supporting evidence is available both
CC       for models with three transmembrane domains (PubMed:15716279 and
CC       PubMed:22923610) and four transmembrane domains (PubMed:20696932
CC       and PubMed:20978134). According to PubMed:15716279 and
CC       PubMed:22923610 the N-terminus of the protein is in the
CC       endoplasmic reticulum lumen, while the C-terminus is in the
CC       cytosol, which is in favor of three transmembrane domains.
CC       According to PubMed:20696932, both N-terminus and C-terminus are
CC       in the cytosol, indicating the presence of four transmembrane
CC       domains. Besides, the 3D-structure of a bacterial ortholog shows
CC       four transmembrane domains. Moreover, proteins that reside in the
CC       endoplasmic reticulum lumen can catalyze the reduction of the
CC       active site cysteines, possibly via Cys-43 and Cys-51
CC       (PubMed:20696932 and PubMed:20978134), but less efficiently than
CC       the synthetic compound dithiothreitol (in vitro). Location of Cys-
CC       43 and Cys-51 in the endoplasmic reticulum lumen would be in
CC       agreement with four transmembrane domains. Again, these data are
CC       controversial, and papers do not agree on the effects of mutating
CC       Cys-43 and Cys-51, probably because of differences in the assay
CC       systems.
CC   -!- DISEASE: Combined deficiency of vitamin K-dependent clotting
CC       factors 2 (VKCFD2) [MIM:607473]: VKCFD leads to a bleeding
CC       tendency that is usually reversed by oral administration of
CC       vitamin K. {ECO:0000269|PubMed:14765194,
CC       ECO:0000269|PubMed:16270630}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Coumarin resistance (CMRES) [MIM:122700]: A condition
CC       characterized by partial or complete resistance to warfarin or
CC       other 4-hydroxycoumarin derivatives. These drugs are used as anti-
CC       coagulants for the prevention of thromboembolic diseases in
CC       subjects with deep vein thrombosis, atrial fibrillation, or
CC       mechanical heart valve replacement. {ECO:0000269|PubMed:14765194,
CC       ECO:0000269|PubMed:20946155}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The location of two cysteine active-site residues
CC       within a proposed transmembrane is consistent both with the known
CC       hydrophobic environment of the thiol redox site of the enzyme and
CC       with the lipophilicity of vitamin K and warfarin (coumadin).
CC   -!- SIMILARITY: Belongs to the VKOR family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ88821.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/vkorc1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY423044; AAR82914.1; -; mRNA.
DR   EMBL; AY521634; AAS01052.1; -; mRNA.
DR   EMBL; AF176924; AAQ13668.1; -; mRNA.
DR   EMBL; AY466113; AAR28759.1; -; mRNA.
DR   EMBL; AY587020; AAS83106.1; -; Genomic_DNA.
DR   EMBL; AK289790; BAF82479.1; -; mRNA.
DR   EMBL; AK312005; BAG34943.1; -; mRNA.
DR   EMBL; AC135050; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471192; EAW52167.1; -; Genomic_DNA.
DR   EMBL; CH471192; EAW52168.1; -; Genomic_DNA.
DR   EMBL; BC002911; AAH02911.1; -; mRNA.
DR   EMBL; AY358456; AAQ88821.1; ALT_INIT; mRNA.
DR   CCDS; CCDS10703.1; -. [Q9BQB6-1]
DR   CCDS; CCDS10704.1; -. [Q9BQB6-3]
DR   RefSeq; NP_001298240.1; NM_001311311.1.
DR   RefSeq; NP_076869.1; NM_024006.5. [Q9BQB6-1]
DR   RefSeq; NP_996560.1; NM_206824.2. [Q9BQB6-3]
DR   UniGene; Hs.324844; -.
DR   ProteinModelPortal; Q9BQB6; -.
DR   BioGrid; 122472; 98.
DR   IntAct; Q9BQB6; 37.
DR   STRING; 9606.ENSP00000378426; -.
DR   BindingDB; Q9BQB6; -.
DR   ChEMBL; CHEMBL1930; -.
DR   DrugBank; DB01418; Acenocoumarol.
DR   DrugBank; DB00266; Dicoumarol.
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB00498; Phenindione.
DR   DrugBank; DB00946; Phenprocoumon.
DR   DrugBank; DB00682; Warfarin.
DR   GuidetoPHARMACOLOGY; 2645; -.
DR   iPTMnet; Q9BQB6; -.
DR   PhosphoSitePlus; Q9BQB6; -.
DR   SwissPalm; Q9BQB6; -.
DR   BioMuta; VKORC1; -.
DR   DMDM; 62511226; -.
DR   EPD; Q9BQB6; -.
DR   MaxQB; Q9BQB6; -.
DR   PaxDb; Q9BQB6; -.
DR   PeptideAtlas; Q9BQB6; -.
DR   PRIDE; Q9BQB6; -.
DR   DNASU; 79001; -.
DR   Ensembl; ENST00000319788; ENSP00000326135; ENSG00000167397. [Q9BQB6-2]
DR   Ensembl; ENST00000354895; ENSP00000346969; ENSG00000167397. [Q9BQB6-3]
DR   Ensembl; ENST00000394975; ENSP00000378426; ENSG00000167397. [Q9BQB6-1]
DR   GeneID; 79001; -.
DR   KEGG; hsa:79001; -.
DR   UCSC; uc002eas.4; human. [Q9BQB6-1]
DR   CTD; 79001; -.
DR   DisGeNET; 79001; -.
DR   GeneCards; VKORC1; -.
DR   H-InvDB; HIX0079837; -.
DR   HGNC; HGNC:23663; VKORC1.
DR   HPA; HPA042720; -.
DR   MalaCards; VKORC1; -.
DR   MIM; 122700; phenotype.
DR   MIM; 607473; phenotype.
DR   MIM; 608547; gene.
DR   neXtProt; NX_Q9BQB6; -.
DR   OpenTargets; ENSG00000167397; -.
DR   Orphanet; 98434; Hereditary combined deficiency of vitamin K-dependent clotting factors.
DR   Orphanet; 413684; Resistance to vitamin K antagonists.
DR   Orphanet; 413674; Vitamin K antagonists toxicity or dose selection.
DR   PharmGKB; PA133787052; -.
DR   eggNOG; ENOG410J0HT; Eukaryota.
DR   eggNOG; ENOG4111UX7; LUCA.
DR   GeneTree; ENSGT00390000002103; -.
DR   HOGENOM; HOG000230752; -.
DR   HOVERGEN; HBG076672; -.
DR   InParanoid; Q9BQB6; -.
DR   KO; K05357; -.
DR   OMA; WSSILLV; -.
DR   OrthoDB; EOG091G0QTR; -.
DR   PhylomeDB; Q9BQB6; -.
DR   TreeFam; TF328467; -.
DR   BRENDA; 1.1.4.1; 2681.
DR   Reactome; R-HSA-6806664; Metabolism of vitamin K.
DR   GeneWiki; VKORC1; -.
DR   GenomeRNAi; 79001; -.
DR   PRO; PR:Q9BQB6; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000167397; -.
DR   CleanEx; HS_VKORC1; -.
DR   ExpressionAtlas; Q9BQB6; baseline and differential.
DR   Genevisible; Q9BQB6; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0048038; F:quinone binding; IEA:UniProtKB-KW.
DR   GO; GO:0047057; F:vitamin-K-epoxide reductase (warfarin-sensitive) activity; IDA:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; IMP:UniProtKB.
DR   GO; GO:0060348; P:bone development; ISS:UniProtKB.
DR   GO; GO:0017144; P:drug metabolic process; IMP:UniProtKB.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; IMP:UniProtKB.
DR   GO; GO:0042373; P:vitamin K metabolic process; IDA:UniProtKB.
DR   InterPro; IPR012932; VKOR.
DR   Pfam; PF07884; VKOR; 1.
DR   SMART; SM00756; VKc; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Disulfide bond; Endoplasmic reticulum; Membrane; Oxidoreductase;
KW   Quinone; Redox-active center; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    163       Vitamin K epoxide reductase complex
FT                                subunit 1.
FT                                /FTId=PRO_0000191668.
FT   TOPO_DOM      1      8       Lumenal. {ECO:0000255}.
FT   TRANSMEM      9     29       Helical. {ECO:0000305}.
FT   TOPO_DOM     30     74       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     75     95       Helical. {ECO:0000255}.
FT   TRANSMEM    101    123       Helical. {ECO:0000305}.
FT   TOPO_DOM    124    126       Lumenal. {ECO:0000305}.
FT   TRANSMEM    127    149       Helical. {ECO:0000305}.
FT   TOPO_DOM    150    163       Cytoplasmic. {ECO:0000305}.
FT   DISULFID    132    135       Redox-active.
FT   VAR_SEQ      59    163       WGRGFGLVEHVLGQDSILNQSNSIFGCIFYTLQLLLGCLRT
FT                                RWASVLMLLSSLVSLAGSVYLAWILFFVLYDFCIVCITTYA
FT                                INVSLMWLSFRKVQEPQGKAKRH -> LPADTLGLCPDAAE
FT                                LPGVSRWFCLPGLDPVLRAL (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043407.
FT   VAR_SEQ      95    163       GCLRTRWASVLMLLSSLVSLAGSVYLAWILFFVLYDFCIVC
FT                                ITTYAINVSLMWLSFRKVQEPQGKAKRH -> DGVSPCCPG
FT                                WSQAICLPQPPKVLGGLQALPADTLGLCPDAAELPGVSRWF
FT                                CLPGLDPVLRAL (in isoform 2).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_013363.
FT   VARIANT      26     26       A -> T (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065785.
FT   VARIANT      29     29       V -> L (in CMRES; dbSNP:rs104894539).
FT                                {ECO:0000269|PubMed:14765194,
FT                                ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_021821.
FT   VARIANT      36     36       D -> G (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065786.
FT   VARIANT      36     36       D -> Y (in CMRES; dbSNP:rs61742245).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065787.
FT   VARIANT      45     45       V -> A (in CMRES; dbSNP:rs104894540).
FT                                {ECO:0000269|PubMed:14765194}.
FT                                /FTId=VAR_021822.
FT   VARIANT      52     52       S -> W (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065788.
FT   VARIANT      56     56       S -> F (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065789.
FT   VARIANT      58     58       R -> G (in CMRES; dbSNP:rs104894541).
FT                                {ECO:0000269|PubMed:14765194}.
FT                                /FTId=VAR_021823.
FT   VARIANT      59     59       W -> C (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065790.
FT   VARIANT      59     59       W -> L (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065791.
FT   VARIANT      66     66       V -> G (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065792.
FT   VARIANT      66     66       V -> M (in CMRES; dbSNP:rs72547529).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065793.
FT   VARIANT      71     71       G -> A (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065794.
FT   VARIANT      77     77       N -> S (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065795.
FT   VARIANT      77     77       N -> Y (in CMRES; dbSNP:rs755767348).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065796.
FT   VARIANT      98     98       R -> W (in VKCFD2; strongly reduced
FT                                enzyme activity; dbSNP:rs72547528).
FT                                {ECO:0000269|PubMed:14765194,
FT                                ECO:0000269|PubMed:16270630}.
FT                                /FTId=VAR_021824.
FT   VARIANT     123    123       I -> N (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065797.
FT   VARIANT     128    128       L -> R (in CMRES; dbSNP:rs104894542).
FT                                {ECO:0000269|PubMed:14765194}.
FT                                /FTId=VAR_021825.
FT   VARIANT     139    139       Y -> H (in CMRES).
FT                                {ECO:0000269|PubMed:20946155}.
FT                                /FTId=VAR_065798.
FT   MUTAGEN      16     16       C->A,S: Reduces enzyme activity by about
FT                                80%. {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN      35     35       R->P: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:15879509}.
FT   MUTAGEN      43     43       C->A,S: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:16270630,
FT                                ECO:0000269|PubMed:20978134}.
FT   MUTAGEN      51     51       C->A,S: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:16270630,
FT                                ECO:0000269|PubMed:20978134}.
FT   MUTAGEN      56     56       S->P: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:15879509}.
FT   MUTAGEN      57     57       S->A: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN      85     85       C->A: Reduces enzyme activity by about
FT                                25%. {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN      85     85       C->S: Reduces enzyme activity by about
FT                                75%. {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN      96     96       C->A,S: Reduces enzyme activity by about
FT                                70%. {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN      98     98       R->D,E: Reduces enzyme activity by about
FT                                80%. Decreases inhibition by warfarin.
FT                                {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN      98     98       R->K: No effect on enzyme activity.
FT                                Decreases inhibition by warfarin.
FT                                {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN     120    120       L->Q: Decreases enzyme activity
FT                                moderately. Decreases inhibition by
FT                                warfarin. {ECO:0000269|PubMed:15879509}.
FT   MUTAGEN     128    128       L->Q,S: Decreases enzyme activity by
FT                                about 80%. Decreases inhibition by
FT                                warfarin. {ECO:0000269|PubMed:15879509}.
FT   MUTAGEN     132    132       C->S: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN     135    135       C->S: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:16270630}.
FT   MUTAGEN     139    139       Y->C,G,S: Decreases enzyme activity
FT                                moderately. Strongly decreases inhibition
FT                                by warfarin.
FT                                {ECO:0000269|PubMed:15879509,
FT                                ECO:0000269|PubMed:16270630}.
FT   MUTAGEN     139    139       Y->F: No effect on enzyme activity.
FT                                Strongly decreases inhibition by
FT                                warfarin. {ECO:0000269|PubMed:15879509,
FT                                ECO:0000269|PubMed:16270630}.
SQ   SEQUENCE   163 AA;  18235 MW;  2F00526A6C561D5A CRC64;
     MGSTWGSPGW VRLALCLTGL VLSLYALHVK AARARDRDYR ALCDVGTAIS CSRVFSSRWG
     RGFGLVEHVL GQDSILNQSN SIFGCIFYTL QLLLGCLRTR WASVLMLLSS LVSLAGSVYL
     AWILFFVLYD FCIVCITTYA INVSLMWLSF RKVQEPQGKA KRH
//
